Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
2020 · Cell · 446 citations
https://doi.org/10.1016/j.cell.2020.06.001
M
Michael Dougan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
329
Papers
13.2K
Citations
52
h-index
120
i10-index
Michael Dougan is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immune Cell Function and Interaction & Immunotherapy and Immune Responses. The author has an h-index of 52, co-authored 280 publications.
ORCID: 0000-0001-9266-2009Papers by this author
worksAGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
2020 · Gastroenterology · 241 citations
https://doi.org/10.1053/j.gastro.2020.08.063
Immune mechanisms of toxicity from checkpoint inhibitors
2023 · Trends in cancer · 217 citations
https://doi.org/10.1016/j.trecan.2023.04.002
Immune‐related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies
2019 · Histopathology · 108 citations
https://doi.org/10.1111/his.13963
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
2018 · The Oncologist · 102 citations
https://doi.org/10.1634/theoncologist.2018-0174
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 · Nature Biotechnology · 73 citations
https://doi.org/10.1038/s41587-022-01510-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat